Articles

Erythropoietin and thrombopoietin

Basser, R. 2002. The impact of thrombopoietin on clinical practice. Current Pharmaceutical Design 8(5), 369-377.

Bottomley, A., Thomas, R., van Steen, K., Flechtner, H., Djulbegovic, B. 2002. Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about? Lancet Oncology 3(3), 145-153.

Buemi, M., Aloisi, C., Cavallaro, E., Corica, F., Floccari, F., Grasso, G., Lasco, A., Pettinato, G, Ruello, A., Sturiale, A., and Frisina, N. 2002. Recombinant human erythropoietin: more than just the correction of uremic anemia. Journal of Nephrology 15(2), 97-103.

Corwin, H. 2006. The role of erythropoietin therapy in the critically ill. Transfusion Medicine Reviews 20(1), 27-33.

Engert, A. 2005. Recombinant human erythropoietin in oncology: current status and further developments. Annals of Oncology 16 (10), 1584-1595.

Fried, W. 1995. Erythropoietin. Annual Review of Nutrition 15, 353-377.

Geddis, A.E., Linden, H.M., and Kaushansky, K. 2002. Thrombopoietin: a pan-hematopoietic cytokine. Cytokine and Growth Factor Reviews 13(1), 61-73.

Heuser, M. and Ganser, A. 2006. Recombinant human erythropoietin in the treatment of nonrenal anemia. Annals of Hematology 85(2), 69-78.

Kaushansky, K. 1997. Thrombopoietin - understanding and manipulating platelet production. Annual Review of Medicine 48, 1-11.

Kaushansky, K. and Drachman, J. 2002. The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. Oncogene 21(21), 3359-3367.

Kaushansky, K. 2005. The molecular mechanisms that control thrombopoiesis. Journal of Clinical Investigation 115(12), 3339-3347.

Kendall, R. 2001. Erythropoietin. Clinical and Laboratory Haematology 23(2), 71-80.

Lok, S., Kaushansky, K., Holly, R.D., Kuijper, J.L., Lofton-Day, C.E., Oort, P.J., Grant, F.J., Heipel, M.D., Burkhead, S.K., Kramer, J.M., Bell, L.A., Sprecher, C.A., Blumberg, H., Johnson, R., Prunkard, D., Ching, A.F.T., Mathewes, S.L., Bailey, M.C., Forstrom, J.W., Buddle, M.M., Osborn, S.G., Evans, S.J., Sheppard, P.O.,

Presnell, S.R., O'Hara, P.J., Hagen, F.S., Roth, G.J., and Foster, D.C. 1994. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 369, 565-568.

Markham, A. and Bryson, H. 1995. Epoetin alfa, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in non-renal applications. Drugs 49(2), 232-254.

Miyazaki, H. and Kato, T. 1999. Thrombopoietin: biology and clinical potential. International Journal of Haematology 70(4), 216-225.

Ogden, J. 1994. Thrombopoietin - the erythropoietin of platelets? Trends in Biotechnology 12, 389-390.

Strauss, R. 2006. Controversies in the management of the anemia of prematurity using single-donor red blood cell transfusions and/or recombinant human erythropoietin. Transfusion Medicine Review 20(1), 34-44.

Colony-stimulating factors

Duarte, R. and Frank, D. 2002. The synergy between stem cell factor (SCF) and granulocyte colony stimulating factor (G-CSF): molecular basis and clinical relevance. Leukaemia and Lymphoma 43(6), 1179-1187.

Esser, M. and Brunner, H. 2003. Economic evaluations of granulocyte colony stimulating factor in the prevention and treatment of chemotherapy-induced neutropenia. Pharmacoeconomics 21(18), 1295-1313.

Fleetwood, A.J., Cook, A.D., and Hamilton, J.A. 2005. Functions of granulocyte-macrophage colony stimulating factor. Critical Reviews in Immunology 25(5), 405-428.

Frampton, J.E., Lee, C.R., and Faulds, D. 1994. Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs 48(5), 731-760.

Frampton, J.E., Yarker, Y.E., and Goa, K.L. 1995. Lenograstim. A review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings. Drugs 49(5), 767-793.

Hamilton, J. 1997. CSF-1 signal transduction. Journal of Leukocyte Biology 62 (2), 145-155.

Harousseau, J. 1997. The role of colony-stimulating factors in the treatment of acute leukaemia. Biodrugs 7(6), 448-460.

Heuser, M. and Ganser, A. 2005. Colony stimulating factors in the management of neutropenia and its complications. Annals of Hematology 84(11), 697-708.

Lyman, G. and Kuderer, N. 2004. The economics of the colony stimulating factors in the prevention and treatment of febrile neutropenia. Critical Review in Oncology and Hematology 50(2), 129-146.

Tabbara, I.A., Ghazal, C.D., and Ghazal, H.H. 1996. The clinical applications of granulocyte-colony-stimulating factor in haematopoietic stem cell transplantation: a review. Anticancer Research 16 (6B), 3901-3905.

Watowich, S.S., Wu, H., Socolovsky, M., Klingmuller, U., Constantinescu, S.N., and Lodish, H.F. 1996. Cytokine receptor signal transduction and the control of haematopoietic cell development. Annual Review of Cell and Developmental Biology 12, 91-128.

Insulin-like growth factors

Bach, L. 1999. The insulin-like growth factor system: basic and clinical aspects. Australian and New Zealand

Journal of Medicine. 29(3), 355-361. Furstenberger, G. and Senn, H. 2002. Insulin like growth factors and cancer. Lancet Oncology, 3(5), 298-302. Kostecka, Z. and Blahovec, J. 2002. Animal insulin-like growth factor binding proteins and their biological functions. Veterinarni Medicina 47(2-3), 75-84. LeRoith, D. 1997. Insulin-like growth factors. New England Journal of Medicine 336(9), 633-640. Schmid, C. 1995. Insulin-like growth factors. Cell Biology International 19(5), 445-457. Yee, D. 2006. Targeting insulin-like growth factor pathways. British Journal of Cancer 94(4), 465-468. Zumkeller, W. 2002. The insulin-like growth factor system in hematopoietic cells. Leukaemia and Lymphoma 43(3), 487-491.

Epidermal growth factor and platelet-derived growth factor

Board, R. and Jayson, G. 2005. Platelet-derived growth factor receptor (PDGFR): a target for anti cancer therapeutics. Drug Resistance Updates 8(1-2), 75-83.

Boonstra, J., Rijken, P., Humbel, B., Cremers, F., Verkleij, A., and van Bergen en Henegouwen, P. 1995. The epidermal growth factor. Cell Biology International 19(5), 413-430.

Johnstone, P. 2002. The epidermal growth factor receptor: a new target for anticancer therapy - introduction. Current Problems in Cancer 26(3), 114-164.

Kane, S. 2006. Cancer therapies targeted to the epidermal growth factor receptor and its family members. Expert Opinion on Therapeutic Patents 16 (2), 147-164.

Leserer, M., Gschwind, A., and Ullrich, A. 2000. Epidermal growth factor receptor signal transactivation. IUBMB Life 49(5), 405-430.

Shih, A. and Holland, E. 2006. Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Letters 232(2), 139-147.

Wakeling, A. 2002. Epidermal growth factor receptor tyrosine kinase inhibitors. Current Opinion in Pharmacology 2(4), 382-387.

Fibroblast growth factor/transforming growth factor

Dennler, S., Goumans, M.J., and ten Dijke, P. 2002. Transforming growth factor beta signal transduction. Journal of Leukocyte Biology 71(5), 731-740. Hu, X. and Zuckerman, K. 2001. Transforming growth factor: signal transduction pathways, cell cycle mediation, and effects on hematopoiesis. Journal of Hematotherapy and Stem Cell Research 10(1), 67-74. Imel, E. and Econs, M. 2005. Fibroblast growth factor 23: roles in health and disease. Journal of the American

Society of Nephrology 16(9), 2565-2575. Kim, I.Y., Kim, M.M., and Kim, S.J. 2005. Transforming growth factor beta: biology and clinical relevance.

Journal of Biochemistry and Molecular Biology 38(1), 1-8. Le, Y., Yu, X., Ruan, L., Wang, O., Qi, D., Zhu, J., Lu, X., Kong, Y., Cai, K., Pang, S., Shi, X., and Wang, J.M. 2005. The immunopharmacological properties of transforming growth factor beta. International Immunopharmacology 9(13-14), 1771-1782. Narayan, S., Thangasamy, T., and Balusu, R. 2005. Transforming growth factor beta receptor signaling in cancer.

Frontiers in Bioscience 10, 1135-1145. Powers, C.J., McLeskey, S.W., and Wellstein, A. 2000. Fibroblast growth factors, their receptors and signalling. Endocrine Related Cancer 7(3), 165-197.

Neurotrophic and related factors

Allen, S. and Dawbarn, D. 2006. Clinical relevance of the neurotropins and their receptors. Clinical Science 110(2), 175-191.

Butte, M. 2001. Neurotrophic factor structure reveals clues to evolution, binding, specificity and receptor activation. Cellular and Molecular Life Sciences 58(8), 1003-1013.

Chao, M.V., Rajagopal, R., and Lee, F.S. 2006. Neurotrophin signaling in health and disease. Clinical Science 110(2), 167-173.

Fu, S. and Gordon, T. 1997. The cellular and molecular basis of peripheral nerve regeneration. Molecular Neurobiology 14, 67-116.

Haque, N.S.K., Borghesani, P., and Isacson, O. 1997. Therapeutic strategies for Huntington's disease, based on a molecular understanding of the disorder. Molecular Medicine Today 3(4), 175-183.

Hefti, F. 1997. Pharmacology of neurotrophic factors. Annual Review of Pharmacology and Toxicology 37, 239-267.

Kwon, Y. 2002. Effect of neurotrophic factors on neuronal stem cell death. Journal of Biochemistry and Molecular Biology 35(1), 87-93.

Sofroniew, M.V., Howe, C.L., and Mobley, W.C. 2001. Nerve growth factor signalling, neuroprotection and neural repair. Annual Review of Neuroscience 24, 1217-1281.

Yamada, K., Mizuno, M., and Nabeshima, T. 2002. Role for brain-derived neurotrophic factor in learning and memory. Life Sciences 70 (7), 735-744.

Thorne, R. and Frey, W. 2001. Delivery of neurotrophic factors to the central nervous system - pharmacokinetic considerations. Clinical Pharmacokinetics 40(12), 907-946.

Tatagiba, M., Brosamle, C., and Schwab, M.E. 1997. Regeneration of injured axons in the adult mammalian central nervous system. Neurosurgery 40(3), 541-546.

Walsh, G. 1995. Nervous excitement over neurotrophic factors. Bio/Technology 13, 1167-1171.

Yamada, M., Ikeuchi, T., and Hatanaka, H. 1997. The neurotrophic action and signalling of epidermal growth factor. Progress in Neurobiology 51(1), 19-37.

Supplements For Diabetics

Supplements For Diabetics

All you need is a proper diet of fresh fruits and vegetables and get plenty of exercise and you'll be fine. Ever heard those words from your doctor? If that's all heshe recommends then you're missing out an important ingredient for health that he's not telling you. Fact is that you can adhere to the strictest diet, watch everything you eat and get the exercise of amarathon runner and still come down with diabetic complications. Diet, exercise and standard drug treatments simply aren't enough to help keep your diabetes under control.

Get My Free Ebook


Post a comment